Case Study

Threshold Pharmaceuticals

  • Geller Biopharm was retained to work with Threshold as its advisor in October of 2008, THLD ~ $0.38/Share
  • Initial work entailed positioning: focusing on breakthrough technology and presentation: building investor appropriate materials
  • Set up non-deal road shows to introduce the story to venture capital groups, buy side and crossover funds, and arranged investor presentations at medical conferences with key opinion leaders and analysts
  • Acquired multiple term sheets for lead investor and arrived at optimal term sheet
  • Finalized book of over $35M in orders, management authorized raise increase to $35M
    • Lead investors included Federated Kaufmann, Frazier and Great Point
  • Closed transaction at $1.91/Share, a 5X increase in price from initiation of the engagement a year earlier (for illustrative purposes only)
  • Past performance is not a guarantee of future results
Geller Biopharm

  Broker / Dealer services provided by Pickwick Capital Partners, LLC. Member FINRA / SIPC

Download our presentation

Get a digital copy of our PDF presentation

Download PDF